Is NeuroPace, Inc. (NPCE) Overvalued?
We dive into why NeuroPace, Inc. (NPCE) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Commentary & Analysis
What You Need to Know About NeuroPace, Inc.'s Q3 Earnings
NeuroPace, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (NPCE) missed or beat analyst's expectations.Jenna Brashear
Why NeuroPace, Inc.’s (NPCE) Stock Is Down 5.45%
As of Wednesday, August 05, NeuroPace, Inc.’s NPCE share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why NeuroPace, Inc.’s (NPCE) Stock Is Down 5.31%
As of Friday, July 31, NeuroPace, Inc.’s NPCE share price has dipped by 5.31%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why NeuroPace, Inc.’s (NPCE) Stock Is Down 5.94%
As of Wednesday, July 29, NeuroPace, Inc.’s NPCE share price has dipped by 5.94%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | NPCE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $500.8 | $382.0 | 37% |
|
| Shares Out (Mil) | 34.1 | 40.8 | 39% |
|
| Institutional Ownership | 94.4% | 83.6% | 65% |
|
| Float (Mil) | 25.5 | 34.7 | 33% |
|
| Beta | 1.94 | 0.88 | 91% |
|
| Avg Daily Volume (000s) | 117 | 274 | 38% |
|
| Price Change (52-week) |
45.8% | 61.6% | 81% |
|
| Growth | NPCE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.5% | 11.8% | 80% |
|
| Net Income (5yr) | 2.4% | (5.8%) | 43% |
|
| EPS (5yr) | 64.6% | 10.4% | 97 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (70.4%) | (15.5%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($0.089) | ($0.442) | ($0.220) | |
| Month Ago EPS | ($0.085) | ($0.445) | ($0.222) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.103) | ($0.560) | ($0.297) | |
| Year/Year Chg | (51.1%) | (32.6%) | (103.0%) | |
| Financials | NPCE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $107 | $119 | 27% |
|
| Net Income (TTM) (Mil) | ($19) | ($9) | 24% |
|
| EPS (TTM) | ($0.569) | ($0.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($3) | 19% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $1 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $68 | $23 | 41% |
|
| Enterprise Value (Q1) (Mil) | $516 | $371 | 34% |
|
| Valuation | NPCE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 41.69 | 2.80 | 98% |
|
| P/E | na | 25.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | NPCE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.4% | 58.3% | 87% |
|
| Net Margin | (17.9%) | (6.9%) | 17% |
|
| ROA | (18.8%) | (12.7%) | 21% |
|
| ROE | (122.1%) | (12.3%) | 8% |
|
| Liabilities to Assets | 87.7% | 46.0% | 82% |
|
| F-Score | 4 | 4 | 33% |
|
NeuroPace, Inc. did not pass any screens on 9/14/2026.
